Dominari (DOMH) Competitors $4.79 +0.19 (+4.13%) As of 04/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DOMH vs. SGMO, LXRX, RGLS, IRWD, ACHV, FBIO, AGEN, BOLT, SABS, and CRISShould you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Regulus Therapeutics (RGLS), Ironwood Pharmaceuticals (IRWD), Achieve Life Sciences (ACHV), Fortress Biotech (FBIO), Agenus (AGEN), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), and Curis (CRIS). These companies are all part of the "biotechnology" industry. Dominari vs. Sangamo Therapeutics Lexicon Pharmaceuticals Regulus Therapeutics Ironwood Pharmaceuticals Achieve Life Sciences Fortress Biotech Agenus Bolt Biotherapeutics SAB Biotherapeutics Curis Dominari (NASDAQ:DOMH) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, community ranking, earnings and analyst recommendations. Is DOMH or SGMO more profitable? Dominari has a net margin of -180.22% compared to Sangamo Therapeutics' net margin of -257.87%. Dominari's return on equity of -32.89% beat Sangamo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dominari-180.22% -32.89% -29.47% Sangamo Therapeutics -257.87%-264.16%-107.24% Which has more volatility and risk, DOMH or SGMO? Dominari has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Do insiders & institutionals believe in DOMH or SGMO? 42.5% of Dominari shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 33.0% of Dominari shares are held by insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer DOMH or SGMO? In the previous week, Sangamo Therapeutics had 1 more articles in the media than Dominari. MarketBeat recorded 3 mentions for Sangamo Therapeutics and 2 mentions for Dominari. Dominari's average media sentiment score of 1.23 beat Sangamo Therapeutics' score of 1.00 indicating that Dominari is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dominari 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sangamo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer DOMH or SGMO? Sangamo Therapeutics has a consensus price target of $5.17, indicating a potential upside of 556.50%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sangamo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has stronger valuation and earnings, DOMH or SGMO? Dominari has higher earnings, but lower revenue than Sangamo Therapeutics. Dominari is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDominari$18.15M2.88-$22.88M-$2.39-2.00Sangamo Therapeutics$57.80M3.06-$257.83M-$0.52-1.51 Does the MarketBeat Community believe in DOMH or SGMO? Sangamo Therapeutics received 456 more outperform votes than Dominari when rated by MarketBeat users. CompanyUnderperformOutperformDominariN/AN/ASangamo TherapeuticsOutperform Votes45662.72% Underperform Votes27137.28% SummarySangamo Therapeutics beats Dominari on 11 of the 17 factors compared between the two stocks. Get Dominari News Delivered to You Automatically Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOMH vs. The Competition Export to ExcelMetricDominariSecurity brokers & dealers IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.27M$29.34B$5.44B$7.80BDividend YieldN/A2.76%5.43%4.30%P/E Ratio-1.2413.8722.1418.40Price / Sales2.885.15389.71101.29Price / CashN/A22.5338.2034.62Price / Book0.482.586.664.18Net Income-$22.88M$1.49B$3.21B$247.71M7 Day Performance20.05%4.79%6.16%6.56%1 Month Performance-4.58%-6.10%-2.86%-2.25%1 Year Performance77.41%25.57%16.43%4.67% Dominari Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOMHDominari0.9543 of 5 stars$4.79+4.1%N/A+77.4%$70.15M$18.15M-1.244Gap DownSGMOSangamo Therapeutics1.3444 of 5 stars$0.75+4.5%$5.17+588.4%+56.5%$168.65M$57.80M-1.00480LXRXLexicon Pharmaceuticals3.3122 of 5 stars$0.53+3.6%$3.67+591.8%-54.0%$130.51M$31.08M-0.71140Upcoming EarningsGap UpRGLSRegulus Therapeutics3.501 of 5 stars$1.91+7.3%$12.75+567.5%+21.6%$126.52MN/A-1.7930Short Interest ↓Positive NewsIRWDIronwood Pharmaceuticals4.3426 of 5 stars$0.65-31.5%$7.80+1,103.9%-89.0%$104.84M$351.41M-21.60220Gap UpHigh Trading VolumeACHVAchieve Life Sciences2.4711 of 5 stars$2.17-0.5%$15.75+625.8%-48.4%$75.61MN/A-1.9220Positive NewsFBIOFortress Biotech2.5961 of 5 stars$1.57+7.5%$21.00+1,237.6%-4.7%$46.37M$57.68M-0.51170Positive NewsAGENAgenus3.3927 of 5 stars$1.78+4.7%$8.75+391.6%-67.5%$45.05M$103.46M-0.16440Analyst RevisionNews CoverageBOLTBolt Biotherapeutics2.983 of 5 stars$0.37+14.3%$1.13+204.1%-66.4%$14.19M$7.69M-0.2290Short Interest ↑News CoveragePositive NewsSABSSAB Biotherapeutics3.2314 of 5 stars$1.39+13.0%$11.40+720.1%-56.4%$11.43M$2.24M-0.38140Short Interest ↓Gap UpCRISCuris2.2742 of 5 stars$1.29+10.3%$21.00+1,527.9%-88.8%$10.95M$10.91M-0.1760Analyst ForecastShort Interest ↑ Related Companies and Tools Related Companies Sangamo Therapeutics Competitors Lexicon Pharmaceuticals Competitors Regulus Therapeutics Competitors Ironwood Pharmaceuticals Competitors Achieve Life Sciences Competitors Fortress Biotech Competitors Agenus Competitors Bolt Biotherapeutics Competitors SAB Biotherapeutics Competitors Curis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DOMH) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIElon Musk has done it again. He’s developed a powerful new AI model that’s already turning heads — and turn...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dominari Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dominari With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DOMH Stock Free DOMH Stock Alerts